October 24, 2025 — A new study in Lancet tells us that we need a fundamental reframing of the medical benefits semaglutide can bring to a growing number of people around the world. In the simplest terms, researchers have found that the heart benefits of semaglutide actually have relatively little to do with weight loss. Professor John Deanfield was […]
September 1, 2025 — Researchers presented and published two major studies of heart disease outcomes at the ESC Congress of the European Society of Cardiology over the weekend with strikingly different findings. In the REBOOT study, scientists found that beta blockers have no effect on outcomes when given to patients after a heart attack. None. People might be better […]
May 13, 2025 — At ECO2025 today, a new analysis from the landmark SELECT trial reveals that heart health benefits with semaglutide can start early for people with obesity and pre-existing heart disease. Within just three months, semaglutide reduced the risk of major cardiovascular events (MACE) by 38% compared to placebo. By six months, this risk dropped by 41%. […]
May 9, 2025 — A new study in JAMA Surgery adds to the impression that long-term outcomes are better with gastric bypass surgery when compared to gastric sleeve procedures for treating obesity. Specifically researchers found that people who have gastric bypass surgery are better than one third less likely to have heart attacks than those who have a gastric […]
April 10, 2025 — It’s a fact. We are eating, drinking, and breathing microplastics. They are accumulating in our bodies – even in our brains. It took painstaking work to figure that out, but even more challenging is the task of nailing down the health effects of all those microplastics. Researchers are doing their best to figure this out. […]
March 30, 2025 — The opening of the American College of Cardiology meeting in Chicago yielded good news on semaglutide from two major studies. A morning presentation and simultaneous publication in Lancet showed semaglutide reduces symptoms of peripheral artery disease in persons with diabetes. Then, in the afternoon, researchers presented data and published it in the New England Journal […]
November 26, 2024 — For the second time this year, we have a meta-analysis of RCTs with GLP-1 medicines that affirms cardiorenal benefits in outcome studies. This latest study appears in Lancet Diabetes and Endocrinology. Lead author Sunil Badve described the importance of his analysis: “This is the first study to show a clear benefit of GLP-1 receptor agonists […]
November 17, 2024 — By 38%, Tirzepatide cuts the risk of bad outcomes in persons with obesity and an increasingly common form of heart failure that obesity causes. The diagnosis is heart failure with preserved ejection fraction or HFpEF. The measure of bad outcomes it prevents was a composite worsening heart failure or death from cardiovascular disease. Worsening heart […]
September 4, 2024 — If nothing else, the ESC (European for Cardiology) Congress in London this week made one thing clear – everyone in mainstream medicine is now ready to claim the disease of obesity. Cardiologists all over the world are adopting a view we’ve been espousing here for decades. Obesity is not a lifestyle. Not a behavioral problem. […]
August 24, 2024 — Novo Nordisk is creeping up on an indication for semaglutide in people with obesity and heart failure. Today in Lancet, we have another piece of the puzzle to suggest this drug might help. In a prespecified analysis from the SELECT study, researchers found that semaglutide reduced heart attacks, strokes, deaths, and problems with heart failure […]
